Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Coya Therapeutics, Inc.NASDAQ: COYA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$7.2M, compared with -$7.3M a year earlier. Trailing-twelve-month EBITDA was -$21.1M.
Context
- EBITDA amounted to 266.8% of revenue in FY2025, down 217.1 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$25.13M (-18.6%) for the fiscal year ending Dec 2026, a step up from the -23.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$7.2M-26.4% QoQ
- Last fiscal yearDec 2025
- -$21.2M-23.2% YoY
- LTMMar 2026
- -$21.1M-18.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.3% | -33.2% | -34.5 pp |
| 1 year | -23.2% | -18.6% | +4.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (21.2M) USD
- Year-over-year change
- -23.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.2M) | -23.2% |
| FY2024 | 2024-12-31 | (17.2M) | -134.5% |
| FY2023 | 2023-12-31 | (7.33M) | +20.8% |
| FY2022 | 2022-12-31 | (9.26M) | -89.9% |
| FY2021 | 2021-12-31 | (4.88M) | — |
EBITDA vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 EBITDA of -$21.1M is the 2nd highest of the 11 companies compared; the peer median is -$43.2M.
- Its year-over-year change of -18.3% is the 7th highest of 11, against a peer median of +0.4%.
- EBITDA amounts to 265.8% of revenue for COYA, versus a peer median of 2480.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M | +1391.3% | — | — | |
| LTM Mar 2026 | -$21.1M | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$29.2M | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$34.56M | -66.8% | — | — | |
| LTM Mar 2026 | -$40.18M | -45.5% | — | — | |
| LTM Mar 2026 | -$46.23M | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$107.98M | +49.6% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M | +37.9% | — | — | |
| Peer median (excluding COYA) | -$43.2M | +0.4% | — | 2480.0% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6M | 3.55M | 7.95M |
| Cost of Revenue | 0 | 4.41M | 5.5M | 11.87M | 27.36K |
| Gross Profit | 0 | (4.41M) | 500.68K | (8.31M) | 7.92M |
| Gross Margin | — | — | 8.3% | -233.9% | 99.7% |
| Research & Development | 2.54M | 4.94M | 6.04M | 11.89M | 16.73M |
| Selling, General & Admin | 2.31M | 4.85M | 7.83M | 8.89M | 11.45M |
| Operating Expenses | 4.87M | 5.4M | 8.4M | 8.94M | 28.18M |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| EBITDA | (4.88M) | (9.26M) | (7.33M) | (17.2M) | (21.2M) |
| EBITDA Margin | — | — | -122.2% | -483.9% | -266.8% |
| Operating Income | (4.87M) | (9.81M) | (7.9M) | (17.25M) | (20.27M) |
| Operating Margin | — | — | -131.7% | -485.4% | -255.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (21.48K) | (2.43M) | 639.37K | 1.65M | (957.4K) |
| Income Before Tax | (4.89M) | (12.24M) | (7.26M) | (15.6M) | (21.22M) |
| Pre-Tax Margin | — | — | -121.0% | -439.0% | -267.1% |
| Income Tax Expense | 0 | 0 | 723.85K | (720.29K) | 3.09K |
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Net Margin | — | — | -133.1% | -418.7% | -267.1% |
| EPS (Basic) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| EPS (Diluted) | (0.74) | (1.23) | (0.79) | (0.98) | (1.27) |
| Weighted Avg Shares | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
| Weighted Avg Shares (Diluted) | 6.6M | 9.95M | 10.16M | 15.24M | 16.73M |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.